Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease
Previously we have shown that a single dose of recombinant adenovirus serotype 26 (Ad26) vaccine expressing a prefusion stabilized SARS-CoV-2 spike antigen (Ad26.COV2.S) is immunogenic and provides protection in Syrian hamster and non-human primate SARS-CoV-2 infection models. Here, we investigated the immunogenicity, protective efficacy, and potential for vaccine-associated enhanced respiratory disease (VAERD) mediated by Ad26.COV2.S in a moderate disease Syrian hamster challenge model, using the currently most prevalent G614 spike SARS-CoV-2 variant. Vaccine doses of 1 × 109 and 1 × 1010 VP elicited substantial neutralizing antibodies titers and completely protected over 80% of SARS-CoV-2 inoculated Syrian hamsters from lung infection and pneumonia but not upper respiratory tract infection. A second vaccine dose further increased neutralizing antibody titers that was associated with decreased infectious viral load in the upper respiratory tract after SARS-CoV-2 challenge. Suboptimal non-protective immune responses elicited by low-dose A26.COV2.S vaccination did not exacerbate respiratory disease in SARS-CoV-2-inoculated Syrian hamsters with breakthrough infection. In addition, dosing down the vaccine allowed to establish that binding and neutralizing antibody titers correlate with lower respiratory tract protection probability. Overall, these preclinical data confirm efficacy of a one-dose vaccine regimen with Ad26.COV2.S in this G614 spike SARS-CoV-2 virus variant Syrian hamster model, show the added benefit of a second vaccine dose, and demonstrate that there are no signs of VAERD under conditions of suboptimal immunity.
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article/Letter to editor biblioteca |
Language: | English |
Subjects: | Life Science, |
Online Access: | https://research.wur.nl/en/publications/ad26cov2s-protects-syrian-hamsters-against-g614-spike-variant-sar |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
dig-wur-nl-wurpubs-581138 |
---|---|
record_format |
koha |
spelling |
dig-wur-nl-wurpubs-5811382025-01-14 van der Lubbe, Joan E.M. Rosendahl Huber, Sietske K. Vijayan, Aneesh Dekking, Liesbeth van Huizen, Ella Vreugdenhil, Jessica Choi, Ying Baert, Miranda R.M. Feddes-de Boer, Karin Izquierdo Gil, Ana van Heerden, Marjolein Dalebout, Tim J. Myeni, Sebenzile K. Kikkert, Marjolein Snijder, Eric J. de Waal, Leon Stittelaar, Koert J. Tolboom, Jeroen T.B.M. Serroyen, Jan Muchene, Leacky van der Fits, Leslie Rutten, Lucy Langedijk, Johannes P.M. Barouch, Dan H. Schuitemaker, Hanneke Zahn, Roland C. Wegmann, Frank Article/Letter to editor npj Vaccines 6 (2021) 1 ISSN: 2059-0105 Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease 2021 Previously we have shown that a single dose of recombinant adenovirus serotype 26 (Ad26) vaccine expressing a prefusion stabilized SARS-CoV-2 spike antigen (Ad26.COV2.S) is immunogenic and provides protection in Syrian hamster and non-human primate SARS-CoV-2 infection models. Here, we investigated the immunogenicity, protective efficacy, and potential for vaccine-associated enhanced respiratory disease (VAERD) mediated by Ad26.COV2.S in a moderate disease Syrian hamster challenge model, using the currently most prevalent G614 spike SARS-CoV-2 variant. Vaccine doses of 1 × 109 and 1 × 1010 VP elicited substantial neutralizing antibodies titers and completely protected over 80% of SARS-CoV-2 inoculated Syrian hamsters from lung infection and pneumonia but not upper respiratory tract infection. A second vaccine dose further increased neutralizing antibody titers that was associated with decreased infectious viral load in the upper respiratory tract after SARS-CoV-2 challenge. Suboptimal non-protective immune responses elicited by low-dose A26.COV2.S vaccination did not exacerbate respiratory disease in SARS-CoV-2-inoculated Syrian hamsters with breakthrough infection. In addition, dosing down the vaccine allowed to establish that binding and neutralizing antibody titers correlate with lower respiratory tract protection probability. Overall, these preclinical data confirm efficacy of a one-dose vaccine regimen with Ad26.COV2.S in this G614 spike SARS-CoV-2 virus variant Syrian hamster model, show the added benefit of a second vaccine dose, and demonstrate that there are no signs of VAERD under conditions of suboptimal immunity. en application/pdf https://research.wur.nl/en/publications/ad26cov2s-protects-syrian-hamsters-against-g614-spike-variant-sar 10.1038/s41541-021-00301-y https://edepot.wur.nl/544790 Life Science https://creativecommons.org/licenses/by/4.0/ https://creativecommons.org/licenses/by/4.0/ Wageningen University & Research |
institution |
WUR NL |
collection |
DSpace |
country |
Países bajos |
countrycode |
NL |
component |
Bibliográfico |
access |
En linea |
databasecode |
dig-wur-nl |
tag |
biblioteca |
region |
Europa del Oeste |
libraryname |
WUR Library Netherlands |
language |
English |
topic |
Life Science Life Science |
spellingShingle |
Life Science Life Science van der Lubbe, Joan E.M. Rosendahl Huber, Sietske K. Vijayan, Aneesh Dekking, Liesbeth van Huizen, Ella Vreugdenhil, Jessica Choi, Ying Baert, Miranda R.M. Feddes-de Boer, Karin Izquierdo Gil, Ana van Heerden, Marjolein Dalebout, Tim J. Myeni, Sebenzile K. Kikkert, Marjolein Snijder, Eric J. de Waal, Leon Stittelaar, Koert J. Tolboom, Jeroen T.B.M. Serroyen, Jan Muchene, Leacky van der Fits, Leslie Rutten, Lucy Langedijk, Johannes P.M. Barouch, Dan H. Schuitemaker, Hanneke Zahn, Roland C. Wegmann, Frank Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease |
description |
Previously we have shown that a single dose of recombinant adenovirus serotype 26 (Ad26) vaccine expressing a prefusion stabilized SARS-CoV-2 spike antigen (Ad26.COV2.S) is immunogenic and provides protection in Syrian hamster and non-human primate SARS-CoV-2 infection models. Here, we investigated the immunogenicity, protective efficacy, and potential for vaccine-associated enhanced respiratory disease (VAERD) mediated by Ad26.COV2.S in a moderate disease Syrian hamster challenge model, using the currently most prevalent G614 spike SARS-CoV-2 variant. Vaccine doses of 1 × 109 and 1 × 1010 VP elicited substantial neutralizing antibodies titers and completely protected over 80% of SARS-CoV-2 inoculated Syrian hamsters from lung infection and pneumonia but not upper respiratory tract infection. A second vaccine dose further increased neutralizing antibody titers that was associated with decreased infectious viral load in the upper respiratory tract after SARS-CoV-2 challenge. Suboptimal non-protective immune responses elicited by low-dose A26.COV2.S vaccination did not exacerbate respiratory disease in SARS-CoV-2-inoculated Syrian hamsters with breakthrough infection. In addition, dosing down the vaccine allowed to establish that binding and neutralizing antibody titers correlate with lower respiratory tract protection probability. Overall, these preclinical data confirm efficacy of a one-dose vaccine regimen with Ad26.COV2.S in this G614 spike SARS-CoV-2 virus variant Syrian hamster model, show the added benefit of a second vaccine dose, and demonstrate that there are no signs of VAERD under conditions of suboptimal immunity. |
format |
Article/Letter to editor |
topic_facet |
Life Science |
author |
van der Lubbe, Joan E.M. Rosendahl Huber, Sietske K. Vijayan, Aneesh Dekking, Liesbeth van Huizen, Ella Vreugdenhil, Jessica Choi, Ying Baert, Miranda R.M. Feddes-de Boer, Karin Izquierdo Gil, Ana van Heerden, Marjolein Dalebout, Tim J. Myeni, Sebenzile K. Kikkert, Marjolein Snijder, Eric J. de Waal, Leon Stittelaar, Koert J. Tolboom, Jeroen T.B.M. Serroyen, Jan Muchene, Leacky van der Fits, Leslie Rutten, Lucy Langedijk, Johannes P.M. Barouch, Dan H. Schuitemaker, Hanneke Zahn, Roland C. Wegmann, Frank |
author_facet |
van der Lubbe, Joan E.M. Rosendahl Huber, Sietske K. Vijayan, Aneesh Dekking, Liesbeth van Huizen, Ella Vreugdenhil, Jessica Choi, Ying Baert, Miranda R.M. Feddes-de Boer, Karin Izquierdo Gil, Ana van Heerden, Marjolein Dalebout, Tim J. Myeni, Sebenzile K. Kikkert, Marjolein Snijder, Eric J. de Waal, Leon Stittelaar, Koert J. Tolboom, Jeroen T.B.M. Serroyen, Jan Muchene, Leacky van der Fits, Leslie Rutten, Lucy Langedijk, Johannes P.M. Barouch, Dan H. Schuitemaker, Hanneke Zahn, Roland C. Wegmann, Frank |
author_sort |
van der Lubbe, Joan E.M. |
title |
Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease |
title_short |
Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease |
title_full |
Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease |
title_fullStr |
Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease |
title_full_unstemmed |
Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease |
title_sort |
ad26.cov2.s protects syrian hamsters against g614 spike variant sars-cov-2 and does not enhance respiratory disease |
url |
https://research.wur.nl/en/publications/ad26cov2s-protects-syrian-hamsters-against-g614-spike-variant-sar |
work_keys_str_mv |
AT vanderlubbejoanem ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease AT rosendahlhubersietskek ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease AT vijayananeesh ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease AT dekkingliesbeth ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease AT vanhuizenella ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease AT vreugdenhiljessica ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease AT choiying ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease AT baertmirandarm ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease AT feddesdeboerkarin ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease AT izquierdogilana ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease AT vanheerdenmarjolein ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease AT dalebouttimj ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease AT myenisebenzilek ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease AT kikkertmarjolein ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease AT snijderericj ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease AT dewaalleon ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease AT stittelaarkoertj ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease AT tolboomjeroentbm ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease AT serroyenjan ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease AT mucheneleacky ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease AT vanderfitsleslie ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease AT ruttenlucy ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease AT langedijkjohannespm ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease AT barouchdanh ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease AT schuitemakerhanneke ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease AT zahnrolandc ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease AT wegmannfrank ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease |
_version_ |
1822266889295888384 |